Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rationale and design of REAC-TAVI 2: Single antiplatelet treatment with ticagrelor vs aspirin after transcatheter aortic valve implantation.

American heart journal·2025
Same author

High Prevalence of <i>hefA</i> Efflux Pump Overexpression in Isolates of <i>Helicobacter pylori</i> Resistant to Clarithromycin.

Antibiotics (Basel, Switzerland)·2025
Same author

Relationship between blood concentration of zinc and selenium and prognosis in post-acute myocardial infarction: A protocol for systematic review and meta-analysis.

PloS one·2025
Same author

Leaflet thrombosis automatic identification in transcatheter aortic valves using 4DCT.

Computers in biology and medicine·2025
Same author

Transcatheter mitral repair in patients with symptomatic moderate functional mitral regurgitation: 1-year outcomes from the MiCLASP study.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2025
Same author

Effect of repeated sprint exercise on immunological responses in adult and adolescent athletes at different stages of biological maturation: a-quasi-experimental-trial.

Scientific reports·2025
Same journal

A follow-up cohort study on secondary findings in cancer predisposition genes from 20,205 Chinese individuals.

Clinica chimica acta; international journal of clinical chemistry·2026
Same journal

Chemometric profiling reveals selective circulating bile acid remodeling in Alzheimer's disease.

Clinica chimica acta; international journal of clinical chemistry·2026
Same journal

Serum sialic acid is independently associated with cerebrovascular atherosclerotic stenosis severity and total vascular burden: A retrospective cohort study.

Clinica chimica acta; international journal of clinical chemistry·2026
Same journal

Measurement of low-density lipoprotein cholesterol and other circulating lipids in Brazil: a systematic literature review.

Clinica chimica acta; international journal of clinical chemistry·2026
Same journal

Reference intervals for venous blood gas measurement in a healthy Chinese population.

Clinica chimica acta; international journal of clinical chemistry·2026
Same journal

Multiplex methylation marker analysis for ctDNA detection in liquid biopsies from anal cancer patients: an HPV-independent approach.

Clinica chimica acta; international journal of clinical chemistry·2026
See all related articles

Related Experiment Videos

Increased clopidogrel response is associated with ABCC3 expression: a pilot study.

André Ducati Luchessi1, Vivian Nogueira Silbiger, Alvaro Cerda

  • 1Faculty of Pharmaceutical Science, Department of Clinical and Toxicological Analyses, University of Sao Paulo, Sao Paulo, Brazil. adluchessi@usp.br

Clinica Chimica Acta; International Journal of Clinical Chemistry
|November 2, 2011
PubMed
Summary
This summary is machine-generated.

Low ABCC3 gene expression in peripheral blood cells is linked to a better response to clopidogrel treatment in coronary artery disease patients. Further research is needed to understand this clopidogrel-ABCC3 relationship.

Related Experiment Videos

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Medicine
  • Molecular Biology

Background:

  • Coronary artery disease (CAD) patients often receive clopidogrel, but responses vary.
  • Gene expression, specifically ABCB1 and ABCC3, may influence clopidogrel efficacy.
  • Investigating these genetic markers can optimize antiplatelet therapy.

Purpose of the Study:

  • To examine the association between ABCB1 and ABCC3 gene expression in peripheral blood cells (PBC) and clopidogrel response in CAD patients.
  • To determine if genetic variations predict treatment outcomes.

Main Methods:

  • Twenty-six male CAD patients (50-70 years) on clopidogrel therapy were studied.
  • Platelet reactivity was measured using P2Y12 Reaction Units (PRU).
  • ABCB1 and ABCC3 mRNA expression levels in PBC were quantified via qPCR.

Main Results:

  • A significant association was found between ABCC3 expression and clopidogrel response.
  • Higher ABCC3 expression correlated with reduced clopidogrel efficacy (1.7 times more expressed in non-responders).
  • Low ABCC3 mRNA expression (Qe1) significantly increased the likelihood of a good clopidogrel response (OR: 18.00, p=0.001).

Conclusions:

  • Reduced ABCC3 mRNA expression in PBC is a potential biomarker for enhanced clopidogrel response in CAD.
  • The functional role of ABCC3 in clopidogrel metabolism and action requires further investigation.